Corticobasal Degeneration
The latest sourced reporting on Corticobasal Degeneration from Dementias Today: dated, and plain about what the evidence does and does not show.
Scientists took tau filaments from the brains of people who had died with Alzheimer's disease or corticobasal degeneration, injected them into ordinary mice, and watched the new tau that grew there copy the original's atomic shape down to the fold. It is the first direct structural check on a long-standing idea: that these misfolded proteins spread the way a stamp spreads its pattern, not the way a rumor changes with each retelling.
A new preprint from a Berkeley structural biology lab used cryo-electron tomography on cultured neurons and astrocytes and found no evidence that tau fibrils tear their way out of lysosomes. The compartments stayed intact. The leak, the authors argue, is something subtler. This is laboratory cell work, not peer reviewed, and not a treatment.
LiBBY, a 120-person randomised trial run at US medical centres with visits in people's homes, met its two-week endpoint on the Cohen-Mansfield Agitation Inventory. The results were presented at a conference in July and have not yet been published in a peer-reviewed journal.
A survey run through the ARTFL research consortium and published as a conference abstract in December 2025 found 91 percent wanted to hear about trials, 43 percent would come in weekly, and the handful who said no were the ones the disease had already stopped. The willingness is on the record. The trials are not.
A model trained on autopsy-confirmed brains was used to pick participants for imaginary trials in progressive supranuclear palsy and corticobasal degeneration. On paper, the numbers needed fell by half for PSP and by 87 percent for CBD. The trials are still imaginary.
A preprint from Mayo Clinic Rochester, not yet peer reviewed, ranked five imaging measures in 32 people with corticobasal syndrome and 35 matched controls. First-generation flortaucipir tau PET came last.